Stocktoria
NewGenIvf Group Ltd NIVF
NewGenIvf Group Ltd (NIVF) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $23.7M at a 41.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.153 |
| Retained earnings / assets | 0.272 |
| EBIT / assets | -0.328 |
| Equity / liabilities | 3.954 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| NIVF | NewGenIvf Group Ltd | 3/9 | 3.84 | 0.6 | — |
| CCEL | CRYO CELL INTERNATIONAL INC | 5/9 | -3.07 | — | -1.3% |
| MGRX | MANGOCEUTICALS, INC. | 2/9 | 2.42 | — | — |
| BRTX | BioRestorative Therapies, Inc. | 3/9 | — | — | — |
| VMD | VIEMED HEALTHCARE, INC. | 5/9 | 5.41 | 26.5 | +20.5% |
| SHC | Sotera Health Co | 6/9 | — | 63.6 | +5.7% |
| PGNY | Progyny, Inc. | 5/9 | 7.14 | 38.2 | +10.4% |
About NewGenIvf Group Ltd
NewGenIvf Group Limited, an investment holding company, provides an assisted reproductive service that helps couples and individuals for fertility treatments in Thailand, Cambodia, Hong Kong, and Kyrgyzstan. The company provides a range of fertility treatment solutions, including in vitro fertilization (IVF), ICSI, embryo culture, hormonal blood tests, infectious diseases tests, chromosome screening, hysteroscopy, sperm analysis, sorting, washing, and freezing, and egg freezing. It also offers IVF treatment; surrogacy and ancillary caring services, and value-added services comprising nutrition guidance, psychological counselling, acupuncture, and translation interpreters to supplement the IVF treatment. The company provides its services through clinics. NewGenIvf Group Limited was founded in 2010 and is based in Bangkok, Thailand.
FAQ
Is NIVF financially healthy?
NewGenIvf Group Ltd's Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does NIVF pay a dividend?
No, NewGenIvf Group Ltd does not currently pay a dividend.
How profitable is NIVF?
In FY2025, NewGenIvf Group Ltd had a net margin of 41.7% and a return on equity of 37.1%.
What is NIVF's P/E ratio?
NewGenIvf Group Ltd's trailing price-to-earnings (P/E) ratio is about 0.6×, based on its latest annual earnings.
What is the analyst price target for NIVF?
The average Wall-Street price target for NewGenIvf Group Ltd is $14.12, about 2595.7% above the recent price, from 1 analysts.
Is NIVF a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on NewGenIvf Group Ltd: a Piotroski F-score of 3/9, an Altman Z″ in the safe zone, a P/E of about 0.6×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.